Answers are grounded in this paper and cite their sources.
Real-world data demonstrate comparable efficacy of CDK4/6 inhibitors in premenopausal metastatic breast cancer, suggesting flexible treatment options.
In real-world peri-/premenopausal patients with HR+/HER2- MBC, ribociclib and palbociclib combined with ET demonstrate comparable efficacy and tolerability. These findings support flexible treatment choice based on individual patient profiles and preferences.
No takes yet. Share an insight, caveat, or question.
Odabaş et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: